Caption Management’s PMV Pharmaceuticals PMVP Stock Holding History

Caption Management’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-11,221	Closed	-$34.8K	–	1588
2023 Q4	$34.8K	Buy	+11,221	New	+$29.7K	﹤0.01%	1237
2022 Q3	–	Sell	-4,285	Closed	-$61K	–	1776
2022 Q2	$61K	Sell	4,285 -19,033	-82%	-$277K	﹤0.01%	1329
2022 Q1	$485K	Buy	+23,318	New	+$411K	0.01%	1148

Other funds holding PMVP

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Caption Management's PMVP Position: Q1 2024 in Review

Caption Management sold out of PMV Pharmaceuticals (PMVP) in Q1 2024, closing a stake of 11,221 shares — an estimated $34.8K sold.

Caption Management first reported a position in PMVP in Q1 2022 and held it in 3 quarters. The position peaked at $485K in Q1 2022. 99 funds tracked by Wall St. Rank hold PMVP as of Q1 2024.

Caption Management reported no remaining PMV Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Caption Management sold 11,221 PMV Pharmaceuticals shares in Q1 2024, an estimated $34.8K.
Caption Management first reported a position in PMV Pharmaceuticals in Q1 2022 and held it in 3 quarters.
Caption Management's PMV Pharmaceuticals position peaked at $485K in Q1 2022.
99 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2024.

Based on Caption Management's 13F filing for Q1 2024, filed 15 May 2024.